Drug Trial Radar · NCT00863681
BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension
Last checked: Nov 20, 2026Latest source record: Nov 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
396
Actual
Start
Mar 12, 2009
Primary completion
Aug 19, 2019
Study completion Aug 19, 2019
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Mar 18, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients who have completed the 12 weeks treatment of the PATENT-1 trial (study number 12934) will be asked to participate in this long term extension study with BAY63-2521.
Conditions
- Hypertension, Pulmonary
Interventions
Riociguat (BAY63-2521)Drug
BAY63-2521: 1mg tid -2.5 mg tid oral until end of study
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-emergent Adverse Events (TEAE)Time frame: From administration of first dose of study medication in PATENT-2 up to 2 days after end of treatment with study medication, up to 10 years and 5 months.
- Number of Participant With DeathTime frame: From baseline to end of safety follow-up visit, up to 10 years and 6 months (1 month more than End of study visit)
Locations
99 sites in 27 countries. Site status is shown where the registry gives one.
Site not named
Los Angeles, California
Site not named
Sacramento, California
Site not named
Aurora, Colorado
Site not named
Boston, Massachusetts
Site not named
Boston, Massachusetts
Site not named
Omaha, Nebraska
Site not named
Cleveland, Ohio
Site not named
Columbus, Ohio
Site not named
Fairfield, Ohio
Site not named
Dallas, Texas
Site not named
El Paso, Texas
Site not named
Capital Federal, Argentina
Site not named
Darlinghurst, New South Wales, Australia
Site not named
Auchenflower, Queensland, Australia
Site not named
Herston, Queensland, Australia
Site not named
Hobart, Tasmania, Australia
Site not named
Prahran, Victoria, Australia
Site not named
Innsbruck, Austria
Site not named
Vienna, Austria
Site not named
Linz, Upper Austria, Austria
Site not named
Bruxelles - Brussel, Belgium
Site not named
Leuven, Belgium
Site not named
Rio de Janeiro, Brazil
Site not named
Porto Alegre, Rio Grande do Sul, Brazil
Site not named
São Paulo, São Paulo, Brazil
Site not named
São Paulo, São Paulo, Brazil
Site not named
Calgary, Alberta, Canada
Site not named
Montreal, Quebec, Canada
Site not named
Beijing, China
Site not named
Beijing, China
Site not named
Shanghai, China
Site not named
Shanghai, China
Site not named
Guangzhou, Guangdong, China
Site not named
Prague, Czechia
Site not named
Aarhus N, Denmark
Site not named
Besançon, France
Site not named
Brest, France
Site not named
Grenoble, France
Site not named
Lille, France
Site not named
Montpellier, France
Showing 40 of 99 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.